A boutique CRDMO redefining product development with our inGenius® platform

Advanced by nature®

Our deep understanding of nature, combined with a suite of advanced technologies, accelerate your product’s journey through key milestones toward commercial success. We are a flexible, reliable and agile partner, offering a bespoke approach for each project.

Ingenza’s impact

100%success rate producing customer targets using one of our hosts
>20xyield enhancement through innovative cell-line and USP development
>70USP and DSP parameters monitored and optimised during process development (in process control)
20years of successful delivery for companies
12Expertise in 12 different biomanufacturing hosts

Pharma solutions

Biologics

Ingenza’s technology platforms will accelerate your development pathway, from drug discovery, through pre-clinical evaluation towards first in human, providing tailored solutions at each stage that meet your timeline with support for all your process, material and analytical needs.

Learn more

Pharma solutions

Small molecule

We have a 20 year history of success engineering efficient microbial production of natural products and the biocatalytic regio- and enantio-selective synthesis of small molecule pharmaceuticals, chiral synthons and advanced intermediates.

Learn more

Sustainable biotech

Ingenza is committed to deploying truly sustainable bioprocesses to meet the environmental and Net Zero objectives of our customers in every industry sector. We enable biomanufacturing to achieve efficiencies of industrial performance, competitiveness and robustness that reduce costs and waste, helping our customers benefit fully from their sustainable manufacturing initiatives.

Learn more

The latest from our news and resources

Deuterium: Slowing Metabolism One C–H Bond At A Time

Deuterium (D) is a heavy stable isotope of hydrogen (H) and is an increasingly utilised strategic modification to improve drug performance  (Di Martino, 2023). The substitution of deuterium isotope for hydrogen offers improved pharmacokinetic performance by extending drug half-life against metabolism…

Continue reading

Nick Challoner appointed as Chief Executive Officer at Ingenza

Ingenza Limited, a technology driven contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as its new Chief Executive Officer, effective the 1st of October, 2025. Nick brings over 30 years of experience in business…

Continue reading